News|Videos|June 11, 2024
The Efficacy, Mechanism of Action for the RSV Vaccines
Author(s)Ann Falsey, MD, Edward Walsh, MD
In part 2 of a 4-part series, clinicians discuss the efficacy, and the mechanism of action of the approved RSV vaccines, including the newly approved Moderna vaccine, mRNA 1345 (mRESVIA).
Advertisement
The FDA approval of the Moderna RSV vaccine, mRNA 1345 (mRESVIA), was based from the results of the phase 3 ConquerRSV trial, which demonstrated an 83.7% efficacy against infection.
As there are now 3 FDA-approved RSV vaccines, Contagion has developed a new short series titled, Special Report: Clinical Insights on Moderna's RSV Vaccine. We have asked RSV vaccine investigators to provide more insights about these immunizations. Ann Falsey, MD, professor of Medicine at the University Of Rochester School Of Medicine, and her colleague, Edward Walsh, MD, professor of Medicine at the University Of Rochester School Of Medicine lead a peer-to-peer discussion on the impact these vaccines may have in preventing this respiratory illness.
In this second episode, Falsey and Walsh discuss the efficacy and mechanism of action of the various RSV vaccines.
Advertisement
Related to this article
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Food expert Lynette Johnston, PhD, provides some context around the ongoing outbreak, discusses prevention, and compares 2026 food recalls with previous years.
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
The Vaccine Integrity Project, in collaboration with the American Medical Association, conducted a vaccine and immunization effectiveness and safety review for RSV, Influenza, and COVID-19 for the 2026-2027 season. JAMA published the review, and here is an overview of the data going into this year's seasonal respiratory virus season.
In the second episode of the series with Perry N. Halkitis, PhD, MS, MPH, he brings his personal experience to this topic and questions whether there should be a shift in who manages the primary care needs of these patients.
Gavin Harris, MD, provides some context around what is happening in the Democratic Republic of Congo regarding the outbreak including the country’s inherent challenges as well as discussing the latest in testing, vaccines, and treatments of this rare strain of Ebola.